Kayo Toyosaki

Multicenter prospective observational study to evaluate the clinical utility of rs61094339 SNP Kit in predicting response to intravesical Bacillus Calmette-Guérin therapy for highest-risk non-muscle-invasive bladder cancer: the PRECISE-BCG study

Takashi Matsumoto, Kayo Toyosaki, Akiyoshi Nakakura, Naomi Takayanagi et autres

Although intravesical Bacillus Calmette-Guérin (BCG) instillation remains the standard of care for patients with highest-risk non-muscle-invasive bladder cancer (NMIBC), nearly 30% of such cases experience disease progression despite adequate treatment. We have identified a single nucleotide polymorphism (SNP), rs61094339 on the X …

jp (code pays fourni par la source)

Efficacy and safety of acotiamide in esophagogastric junction outflow obstruction: a placebo-controlled phase II trial

Eikichi Ihara, Haruei Ogino, Mitsuru Esaki, Noriaki Manabe et autres

jp (code pays fourni par la source)

Biology and evolving management of resectable dMMR/MSI-H cancers: current status and future perspectives

Tokiyoshi Tanegashima, Masaki Shiota, Kayo Toyosaki, Kouta Funakoshi et autres

Mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) tumors represent a biologically and immunologically distinct subset of solid malignancies. Defective DNA mismatch repair mechanisms in these tumors lead to the accumulation of insertion-deletion mutations, a hypermutated phenotype, and abundant tumor-specific neoantigens. These features …

jp (code pays fourni par la source)

Recurrence monitoring using ctDNA in patients with metastatic colorectal cancer: COSMOS-CRC-03 and AURORA studies

Eiji Oki, Ryota Nakanishi, Koji Ando, Ichiro Takemasa et autres

International treatment guidelines recommend tumor resection for patients with oligometastatic colorectal cancer (CRC). Despite this, recurrence occurs in ∼60% of patients post-surgery, indicating that the role and optimal type of perioperative systemic therapy has not been fully defined. In the COSMOS-oligo trials, …

jp (code pays fourni par la source)

Recurrence monitoring using ctDNA in patients with metastasis of colorectal cancer: COSMOS- oligo study

Eiji Oki, Ryota Nakanishi, Koji Ando, Sho Nambara et autres

Abstract The best treatment strategy for resectable metastatic colorectal cancer is surgical resection of the metastatic site. However, approximately 60% of patients show recurrence after the resection of metastatic lesions, and some patients require aggressive perioperative chemotherapy. We initiated new trials to …

jp (code pays fourni par la source)

Prospective trial of biodegradable stents for refractory benign esophageal strictures after curative treatment of esophageal cancer

Tomonori Yano, Yusuke Yoda, Shogo Nomura, Kayo Toyosaki et autres

jp (code pays fourni par la source)

Phase I trial of GBS ‐01 for advanced pancreatic cancer refractory to gemcitabine

Masafumi Ikeda, Akihiro Sato, Nobuo Mochizuki, Kayo Toyosaki et autres

GBS-01, an extract from the fruit of Arctium lappa L. is an orally administered drug rich in arctigenin, which has been reported to exert antitumor activity by attenuating the tolerance of cancer cells to glucose deprivation. We investigated the maximum tolerated dose …

jp (code pays fourni par la source)

Tu1230 Prospective Trial of Biodegradable Stents (BD Stent) for Refractory Benign Esophageal Strictures After Curative Treatment of Esophageal Cancer (UMIN000008054)

Masaki Tanaka, Tomonori Yano, Yusuke Yoda, Shogo Nomura et autres

jp (code pays fourni par la source)

A phase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine.

Masafumi Ikeda, Akihiro Sato, Nobuo Mochizuki, Kayo Toyosaki et autres

2559 Background: Arctigenin, which is abundant in the seeds of Arctium lappa Linné, was found by a novel strategy to attenuate cancer cells’ tolerance to glucose deprivation (antiausterity) and showed antitumor activity in mouse xenograft models. GBS-01 is an orally administered drug …

jp (code pays fourni par la source)

[Establishment and clinical effectiveness of an HLA-typed donor registration system].

Chiaki Araki, Hisakata Nagahashi, Kayo Toyosaki, K. Sawayama et autres